Mylan to buy Abbott's non-US specialty, branded generics assets

July 14 (Reuters) - Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.